GCP
SLXP

GSA Capital Partners’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

GSA Capital Partners’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,748
Closed -$546K – 2335
2014
Q4 		$546K Buy
4,748
+1,966
+71% +$238K 0.04% 875
2014
Q3 		$435K Buy
+2,782
New +$403K 0.02% 1023

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSA Capital Partners's SLXP Position: Q1 2015 in Review

GSA Capital Partners sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 4,748 shares — an estimated $546K sold.

GSA Capital Partners first reported a position in SLXP in Q3 2014 and held it in 2 quarters. The position peaked at $546K in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • GSA Capital Partners reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • GSA Capital Partners sold 4,748 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $546K.
  • GSA Capital Partners first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 2 quarters.
  • GSA Capital Partners's SALIX PHARMACEUTICALS LTD DEL position peaked at $546K in Q4 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on GSA Capital Partners's 13F filing for Q1 2015, filed 14 May 2015.